Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib + Abiraterone in Japanese mCRPC
NCT04071262Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Eli Lilly and Company. Primary endpoint: Dose Limiting Toxicities. Started Dec 2019; status: completed.
02
Drugs
abemaciclib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04071262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04071262.